Bank of New York Mellon Corp Has $2.37 Million Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Bank of New York Mellon Corp trimmed its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 220,249 shares of the biotechnology company’s stock after selling 4,731 shares during the period. Bank of New York Mellon Corp owned 0.26% of Anavex Life Sciences worth $2,365,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Orion Capital Management LLC increased its stake in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares during the period. PVG Asset Management Corp bought a new position in shares of Anavex Life Sciences during the third quarter worth approximately $74,000. Atria Investments Inc bought a new position in shares of Anavex Life Sciences during the third quarter worth approximately $76,000. BNP Paribas Financial Markets increased its stake in shares of Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 7,421 shares during the period. Finally, Erste Asset Management GmbH bought a new position in shares of Anavex Life Sciences during the third quarter worth approximately $102,000. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $9.74 on Friday. The stock has a 50 day moving average price of $9.10 and a two-hundred day moving average price of $8.14. The firm has a market capitalization of $828.52 million, a P/E ratio of -17.71 and a beta of 0.94. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, equities analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVXL has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 18th. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.